BL-918 is an orally active UNC-51-like kinase 1 (ULK1) activator with an EC50 of 24.14 nM. BL-918 exerts its cytoprotective autophagic effect by targeting ULK complex. BL-918 has the potential for Parkinson’s disease (PD) treatment.
体外研究
BL-918 (compound 33i) binds to ULK1 with a high binding affinity (KD=0.719 μM).
BL-918 (5 μM; for 24 hours) induces autophagy in Neuron-Like SH-SY5Y cells.
BL-918 (0.5-50 μM; for 24 hours) can partially reverse MPP-induced cell death, which is determined by enhancing cell viability.
BL-918 (5 μM; for 6-36 hours) time-dependently elevates the expression levels of LC3-II, Beclin-1, and its phosphorylation status, whereas reduces the level of the selective autophagy substrate SQSTM1/p62. BL-918 elevates Ser317 and Ser555 phosphorylation of ULK1, as well as decreases Ser757 phosphorylation of ULK1.
Cell Autophagy Assay
Cell Line:
SH-SY5Y cells
Concentration:
5 μM
Incubation Time:
For 24 hours
Result:
Induced Autophagy.
Cell Viability Assay
Cell Line:
SH-SY5Y cells
Concentration:
0.5, 5, 50 μM
Incubation Time:
For 24 hours
Result:
Could partially reverse MPP-induced cell death, which was determined by enhancing cell viability.
Western Blot Analysis
Cell Line:
SH-SY5Y cells
Concentration:
5 μM
Incubation Time:
6, 12, 24, 36 hours
Result:
Time-dependently elevated the expression levels of LC3-II (a key marker of autophagy), Beclin-1, and its phosphorylation status, whereas reduced the level of the selective autophagy substrate SQSTM1/p62.
体内研究
BL-918 (compound 33i; 20, 40, or 80 mg/kg/day; oral gavage; began 2 days before the first injection of saline/MPTP and continuously maintained for 5 days after the last injection of saline/MPTP) attenuates the loss of DA and its metabolites. BL-918 obviously decreases the levels of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA).
Animal Model:
Male C57BL/6 mice (eight-week old) weighing between 20 and 25 g
Dosage:
20, 40, or 80 mg/kg
Administration:
Oral gavage; daily; began 2 days before the first injection of saline/MPTP and continuously maintained for 5 days after the last injection of saline/MPTP
Result:
Attenuated the loss of DA and its metabolites.
分子式
C23H15F8N3Os
分子量
533.44
CAS号
2101517-69-3
运输条件
Room temperature in continental US; may vary elsewhere.